EFFECTIVENESS AGAINST PNEUMONIA
The complexity of interpreting postmarketing impact studies is perhaps best illustrated by a study from Sweden [15] referred to also by Farkouh et al. [1] , where currently both PHiD-CV and PCV-13 are used in different county councils. Differences in pneumonia hospitalization incidence were observed between the respective councils and it was suggested that this can be attributed to the difference in the valence of PCVs used [1].
However, as reported in that paper [15] , the seven-valent PCV (PCV-7) was introduced in all those councils in Sweden prior to the use of higher valent vaccines, and yet the magnitude of reduction of pneumonia incidence observed during the period when only PCV-7 was used still differed markedly in those respective councils, which are currently using either PCV-13 or PHiD-CV. This observation strongly suggests that any observed differences in pneumonia incidence between the councils mainly reflect other epidemiological factors or secular trends that differ in the two populations, rather than true differences in efficacy against pneumonia of either PCV-13 or PHiD-CV. In conclusion, the concept that overall protection is governed predominantly by serotype coverage is unsupported by the clinical evidence [3] and support the efficacy estimates used in our published model [2] . was similar, so it is reasonable to assume that it would not be a lot different for PCV-13.
PROTECTION AGAINST CROSS-REACTIVE SEROTYPES
With respect to efficacy against NTHi-AOM, although the COMPAS trial was not powered to 
EFFECTIVENESS AGAINST IPD CAUSED BY SEROTYPE 3
Farkouh et al. [54] against serotype 3 IPD was tested in the sensitivity analysis of our model, revealing no substantial impact on the model outcome.
HERD EFFECT

Farkouh et al. [1] question whether indirect
effects for VT disease have been demonstrated and reported for both formulations, i.e., both PCV-13 and PHiD-CV. Decreases in VT disease in non-vaccinated cohorts have been observed in post-marketing studies for both PCV-13 and PHiD-CV (including Brazil, Chile, Finland and Iceland [55] ). In addition, the herd effect of PHiD-CV has been more rigorously analyzed in the context of a cluster randomized doubleblind study in Finland [56] .
Although not mentioned by Farkouh et al.
[1], the public health value of the herd effects remains an area of debate. Based on the experience with PCV-7 use, the herd effect observed for VT disease is likely to be largely or fully offset by disease caused by circulating non-vaccine serotypes, a phenomenon called serotype replacement [57, 58] . The extent of such replacement elicited by each of the new vaccines is a remaining area of uncertainty, and therefore whether there will be differential net herd effect is currently difficult to assess conclusively [3] . In consequence, we did not incorporate herd or indirect protection in our analysis. Further discussion on the reasons why herd effects were not considered for this analysis is detailed in our original paper [2].
SUMMARY
Our analysis has considered the most up-to-date clinical evidence, placing emphasis on data from randomized double-blind controlled trials, rather than having relied on theoretical assumptions. In addition, we have consulted an external group of experts to validate each parameter that was used as base-case input into the model. We hope that the evidence provided here, in addition to what is reflected in our original paper, testifies that we have considered the strengths and weaknesses of all available data to construct a sensible and conservative base-case analysis as well as have meticulously addressed any areas of uncertainty using appropriate sensitivity and scenario analyses.
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